U.S.-based pharmaceutical major Eli Lilly and Co. $LLY has entered into a definitive agreement to acquire Verve Therapeutics Inc. $VERV, a clinical-stage biotech innovator focused on gene-editing ther...

Anne Wojcicki, co-founder and former CEO of the bankrupt genetic testing company 23andMe $ME, has emerged as the winning bidder in a court-supervised auction for the firm's core asset: a massive repos...

The genetic testing company 23andMe $ME, which filed for bankruptcy earlier this year, has informed the U.S. bankruptcy court of its intention to reopen the auction process for the sale of its assets,...

Sanofi and Regeneron Pharmaceuticals faced notable share price declines after mixed results from late-stage clinical trials of their experimental drug, itepekimab, targeting chronic obstructive pulmon...

In a notable move underscoring the growing integration of genomic data into pharmaceutical R&D, Regeneron Pharmaceuticals Inc. $REGN announced on Monday its acquisition of the bankrupt consumer geneti...

Biotech heavyweight Regeneron Pharmaceuticals Inc. $REGN reported weaker-than-expected first-quarter results on Tuesday, primarily due to a decline in revenue from its flagship eye drug Eylea. The dis...